Cardiff Lexingto Financials

CDIX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Cardiff Lexingto (CDIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 23 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 6/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Cardiff Lexingto has an operating margin of -2.3%, meaning the company retains $-2 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 43.8% the prior year.

Growth

Cardiff Lexingto's revenue declined 30.2% year-over-year, from $11.9M to $8.3M. This contraction results in a growth score of 0/100.

Leverage

Cardiff Lexingto has elevated debt relative to equity (D/E of 3.43), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Cardiff Lexingto's current ratio of 1.08 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 23/100, which could limit financial flexibility.

Piotroski F-Score Weak

2/9

Cardiff Lexingto passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.84x

For every $1 of reported earnings, Cardiff Lexingto generates $0.84 in operating cash flow (-$2.8M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

$8.3M

YoY-30.2%

5Y CAGR+17.4%

10Y CAGR+25.0%

Cardiff Lexingto generated $8.3M in revenue in fiscal year 2024. This represents a decrease of 30.2% from the prior year.

EBITDA

-$180K

YoY-103.5%

Cardiff Lexingto's EBITDA was -$180K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 103.5% from the prior year.

Free Cash Flow

N/A

Net Income

-$3.3M

YoY-209.1%

Cardiff Lexingto reported -$3.3M in net income in fiscal year 2024. This represents a decrease of 209.1% from the prior year.

EPS (Diluted)

$-0.37

Cardiff Lexingto earned $-0.37 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 100.2% from the prior year.

Cash & Debt

$1.2M

YoY+37.1%

5Y CAGR+63.8%

10Y CAGR+38.3%

Cardiff Lexingto held $1.2M in cash against $9.2M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

15M

Cardiff Lexingto had 15M shares outstanding in fiscal year 2024. This represents an increase of 60807.1% from the prior year.

Gross Margin

53.5%

YoY-16.4pp

5Y CAGR-1.5pp

10Y CAGR+27.0pp

Cardiff Lexingto's gross margin was 53.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 16.4 percentage points from the prior year.

Operating Margin

-2.3%

YoY-46.2pp

5Y CAGR+31.9pp

10Y CAGR+1396.2pp

Cardiff Lexingto's operating margin was -2.3% in fiscal year 2024, reflecting core business profitability. This is down 46.2 percentage points from the prior year.

Net Margin

-39.9%

YoY-65.5pp

5Y CAGR+153.7pp

10Y CAGR+1434.9pp

Cardiff Lexingto's net profit margin was -39.9% in fiscal year 2024, showing the share of revenue converted to profit. This is down 65.5 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

CDIX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$8.3M-30.2%	$11.9M+10.8%	$10.7M+8.2%	$9.9M+186.1%	$3.5M-6.9%	$3.7M
Cost of Revenue	$3.8M+7.9%	$3.6M-12.3%	$4.1M+7.7%	$3.8M+125.9%	$1.7M+0.2%	$1.7M
Gross Profit	$4.4M-46.6%	$8.3M+25.0%	$6.6M+8.6%	$6.1M+242.3%	$1.8M-12.6%	$2.0M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$4.1M+32.1%	$3.1M+13.8%	$2.7M-39.0%	$4.4M+23.6%	$3.6M+8.5%	$3.3M
Operating Income	-$194K-103.7%	$5.2M+33.0%	$3.9M+135.1%	$1.7M+192.1%	-$1.8M-41.9%	-$1.3M
Interest Expense	N/A	$440K-2.9%	$453K	N/A	$144K-70.6%	$489K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.3M-209.1%	$3.0M+155.8%	-$5.4M-914.9%	$666K+123.5%	-$2.8M+60.5%	-$7.2M
EPS (Diluted)	$-0.37	$149.88	$-999.00	$-0.01	$-4.98	$-282.66

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$3.1M+9.7%	$2.8M-4.3%	$2.9M-6.6%	$3.1M+112.1%	$1.5M-36.6%	$2.3M-2.3%	$2.4M-30.2%	$3.4M
Cost of Revenue	$1.1M+5.1%	$1.1M+1.7%	$1.1M-2.3%	$1.1M+38.7%	$793K-16.4%	$948K-2.4%	$971K+76.1%	$551K
Gross Profit	$1.9M+12.6%	$1.7M-7.9%	$1.8M-8.9%	$2.0M+197.8%	$679K-50.6%	$1.4M-2.2%	$1.4M-50.8%	$2.9M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.2M+24.0%	$987K-22.9%	$1.3M-11.1%	$1.4M+72.6%	$835K-2.0%	$851K-13.2%	$981K+69.9%	$578K
Operating Income	$643K+5.5%	$610K+12.1%	$544K+63.8%	$332K+308.3%	-$159K-172.8%	$219K-47.2%	$415K-81.8%	$2.3M
Interest Expense	$1.8M-3.8%	$1.8M+84.9%	$993K-28.3%	$1.4M+3252.2%	$41K-61.5%	$107K+114.6%	-$738K-426.2%	$226K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.1M+6.7%	-$1.2M-172.1%	-$451K+50.5%	-$910K-591.8%	-$132K+53.5%	-$283K-214.7%	$247K-87.5%	$2.0M
EPS (Diluted)	$-0.07+12.5%	$-0.08-60.0%	$-0.05+16.7%	$-0.06-50.0%	$-0.04+63.6%	$-0.11	$174.33	$2.30

CDIX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$23.9M+15.3%	$20.7M+55.5%	$13.3M-12.8%	$15.3M+210.3%	$4.9M+0.3%	$4.9M
Current Assets	$17.2M+21.4%	$14.2M+107.6%	$6.8M+3.6%	$6.6M+2129.5%	$296K+58.4%	$187K
Cash & Equivalents	$1.2M+37.1%	$867K+295.7%	$219K-62.3%	$581K+108.0%	$279K+177.2%	$101K
Inventory	N/A	N/A	N/A	N/A	N/A	$3K
Accounts Receivable	$15.9M+19.8%	$13.3M+101.5%	$6.6M+9.9%	$6.0M+36575.8%	$16K-83.5%	$100K
Goodwill	$5.7M0.0%	$5.7M0.0%	$5.7M-27.0%	$7.8M0.0%	$7.8M+121.7%	$3.5M
Total Liabilities	$21.2M+6.1%	$20.0M+32.6%	$15.1M+1.9%	$14.8M+7.3%	$13.8M+18.6%	$11.6M
Current Liabilities	$15.9M+14.6%	$13.9M+39.1%	$10.0M-10.8%	$11.2M-16.6%	$13.4M+24.7%	$10.7M
Long-Term Debt	$9.2M+303.8%	$2.3M+1365.8%	$156K-74.1%	$601K	N/A	N/A
Total Equity	$2.7M+267.1%	$731K+141.9%	-$1.7M-458.4%	$487K+105.5%	-$8.9M-31.9%	-$6.7M
Retained Earnings	-$72.9M-6.2%	-$68.7M+3.2%	-$70.9M-8.9%	-$65.1M+0.7%	-$65.6M-4.8%	-$62.6M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$27.6M+4.1%	$26.5M+4.7%	$25.3M+5.9%	$23.9M-3.1%	$24.7M+9.3%	$22.6M+9.0%	$20.7M+12.0%	$18.5M
Current Assets	$21.0M+5.9%	$19.9M+6.8%	$18.6M+8.1%	$17.2M-4.7%	$18.1M+13.5%	$15.9M+12.2%	$14.2M+17.8%	$12.0M
Cash & Equivalents	$232K-58.5%	$560K-43.8%	$997K-16.1%	$1.2M-62.8%	$3.2M+155.0%	$1.3M+44.6%	$867K+378.4%	$181K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$20.7M+7.8%	$19.2M+9.7%	$17.5M+9.8%	$15.9M+7.2%	$14.9M+1.4%	$14.6M+10.1%	$13.3M+12.3%	$11.8M
Goodwill	$5.7M0.0%	$5.7M0.0%	$5.7M0.0%	$5.7M0.0%	$5.7M0.0%	$5.7M0.0%	$5.7M0.0%	$5.7M
Total Liabilities	$22.6M+10.0%	$20.5M+12.7%	$18.2M-14.2%	$21.2M+49.6%	$14.2M-33.6%	$21.4M+6.9%	$20.0M+12.2%	$17.8M
Current Liabilities	$22.4M+10.3%	$20.3M+13.4%	$17.9M+12.6%	$15.9M+14.4%	$13.9M-7.4%	$15.0M+8.2%	$13.9M+16.5%	$11.9M
Long-Term Debt	$15.1M+15.0%	$13.1M+22.5%	$10.7M+16.2%	$9.2M+25.0%	$7.4M+96.8%	$3.7M+64.2%	$2.3M+1247.4%	$169K
Total Equity	-$364K-148.4%	$754K-63.0%	$2.0M-24.2%	$2.7M-54.3%	$5.9M+386.0%	$1.2M+65.4%	$731K+8.2%	$676K
Retained Earnings	-$76.5M-1.9%	-$75.1M-2.0%	-$73.6M-1.0%	-$72.9M-4.8%	-$69.6M-0.7%	-$69.1M-0.6%	-$68.7M0.0%	-$68.7M

CDIX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$2.8M-60.7%	-$1.7M-49.6%	-$1.2M-35.4%	-$850K+5.9%	-$903K+13.8%	-$1.0M
Capital Expenditures	N/A	N/A	$0-100.0%	$3K	$0	N/A
Free Cash Flow	N/A	N/A	-$1.2M-34.8%	-$854K+5.5%	-$903K	N/A
Investing Cash Flow	N/A	N/A	$0+100.0%	-$2.3M	N/A	$32K
Financing Cash Flow	$3.0M+25.6%	$2.4M+200.4%	$789K-78.5%	$3.7M+219.6%	$1.2M+60.3%	$718K
Dividends Paid	N/A	$780K+131.7%	$337K	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$574K+58.9%	-$1.4M-184.4%	-$491K+32.0%	-$723K-620.5%	-$100K+90.3%	-$1.0M+11.1%	-$1.2M-291.8%	-$297K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$247K-74.3%	$961K+220.2%	$300K+872.1%	-$39K-101.9%	$2.0M+56.0%	$1.3M-27.7%	$1.8M+2511.8%	$69K
Dividends Paid	$0	$0-100.0%	$50K	$0-100.0%	$100K	$0-100.0%	$780K	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CDIX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	53.5%-16.4pp	70.0%+7.9pp	62.0%+0.2pp	61.9%+10.2pp	51.7%-3.4pp	55.1%
Operating Margin	-2.3%-46.2pp	43.8%+7.3pp	36.5%+19.7pp	16.8%+69.1pp	-52.3%-18.0pp	-34.3%
Net Margin	-39.9%-65.5pp	25.6%+76.3pp	-50.8%-57.5pp	6.7%+88.9pp	-82.2%+111.5pp	-193.7%
Return on Equity	N/A	414.0%	N/A	136.9%	N/A	N/A
Return on Assets	-13.8%-28.4pp	14.6%+55.3pp	-40.7%-45.1pp	4.4%+61.9pp	-57.5%+88.5pp	-146.1%
Current Ratio	1.08+0.1	1.02+0.3	0.69+0.1	0.59+0.6	0.020.0	0.02
Debt-to-Equity	3.43+0.3	3.12+3.2	-0.09-1.3	1.23+2.8	-1.56+0.2	-1.73
FCF Margin	N/A	N/A	-10.8%-2.1pp	-8.6%+17.5pp	-26.2%	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	62.4%+1.6pp	60.8%-2.3pp	63.1%-1.6pp	64.8%+18.6pp	46.1%-13.1pp	59.2%+0.0pp	59.1%-24.7pp	83.8%
Operating Margin	21.0%-0.8pp	21.9%+3.2pp	18.7%+8.0pp	10.6%+21.5pp	-10.8%-20.3pp	9.4%-8.0pp	17.4%-49.3pp	66.8%
Net Margin	-37.4%+6.6pp	-44.0%-28.5pp	-15.5%+13.7pp	-29.2%-20.2pp	-8.9%+3.3pp	-12.2%-22.6pp	10.4%-47.8pp	58.2%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	33.7%-259.5pp	293.3%
Return on Assets	-4.1%+0.5pp	-4.6%-2.9pp	-1.8%+2.0pp	-3.8%-3.3pp	-0.5%+0.7pp	-1.3%-2.4pp	1.2%-9.5pp	10.7%
Current Ratio	0.94-0.0	0.98-0.1	1.04-0.0	1.08-0.2	1.30+0.2	1.06+0.0	1.02+0.0	1.01
Debt-to-Equity	-41.35-58.7	17.39+12.1	5.26+1.8	3.43+2.2	1.25-1.8	3.09-0.0	3.12+2.9	0.25
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Numinus Wellness Inc. NUMIF

$11.7M

Xcelerate Inc XCRT

$7.3M

Selectis Health Inc GBCS

$6.1M

Biocorrx Inc BICX

$8.5M

Veltex VLXC

$7.9M

Frequently Asked Questions

What is Cardiff Lexingto's annual revenue?

Cardiff Lexingto (CDIX) reported $8.3M in total revenue for fiscal year 2024. This represents a -30.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cardiff Lexingto's revenue growing?

Cardiff Lexingto (CDIX) revenue declined by 30.2% year-over-year, from $11.9M to $8.3M in fiscal year 2024.

Is Cardiff Lexingto profitable?

No, Cardiff Lexingto (CDIX) reported a net income of -$3.3M in fiscal year 2024, with a net profit margin of -39.9%.

What is Cardiff Lexingto's earnings per share (EPS)?

Cardiff Lexingto (CDIX) reported diluted earnings per share of $-0.37 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Cardiff Lexingto's EBITDA?

Cardiff Lexingto (CDIX) had EBITDA of -$180K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Cardiff Lexingto have?

As of fiscal year 2024, Cardiff Lexingto (CDIX) had $1.2M in cash and equivalents against $9.2M in long-term debt.

What is Cardiff Lexingto's gross margin?

Cardiff Lexingto (CDIX) had a gross margin of 53.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Cardiff Lexingto's operating margin?

Cardiff Lexingto (CDIX) had an operating margin of -2.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Cardiff Lexingto's net profit margin?

Cardiff Lexingto (CDIX) had a net profit margin of -39.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Cardiff Lexingto's operating cash flow?

Cardiff Lexingto (CDIX) generated -$2.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Cardiff Lexingto's total assets?

Cardiff Lexingto (CDIX) had $23.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Cardiff Lexingto have outstanding?

Cardiff Lexingto (CDIX) had 15M shares outstanding as of fiscal year 2024.

What is Cardiff Lexingto's current ratio?

Cardiff Lexingto (CDIX) had a current ratio of 1.08 as of fiscal year 2024, which is considered adequate.

What is Cardiff Lexingto's debt-to-equity ratio?

Cardiff Lexingto (CDIX) had a debt-to-equity ratio of 3.43 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cardiff Lexingto's return on assets (ROA)?

Cardiff Lexingto (CDIX) had a return on assets of -13.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Cardiff Lexingto's cash runway?

Based on fiscal year 2024 data, Cardiff Lexingto (CDIX) had $1.2M in cash against an annual operating cash burn of $2.8M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Cardiff Lexingto's Piotroski F-Score?

Cardiff Lexingto (CDIX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cardiff Lexingto's earnings high quality?

Cardiff Lexingto (CDIX) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Cardiff Lexingto?

Cardiff Lexingto (CDIX) scores 6 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.